| UHC Commercial Medical & Drug | Roctavian® (Valoctocogene Roxaparvovec-Rvox) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sacral Nerve Stimulation for Urinary and Fecal Indications – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Sensory Integration Therapy and Auditory Integration Training – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Spinal Fusion and Bone Healing Enhancement Products – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Subcutaneous Implantable Naltrexone Pellets – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Surgery for the Prevention and Treatment of Lymphedema – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Surgery of the Hand or Wrist – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Testosterone Replacement or Supplementation Therapy – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Transarterial Radioembolization (TARE)/ Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Vagus and External Trigeminal Nerve Stimulation – Commercial and Individual Exchange Medical Policy | 2026-01-01 |